 |
市場調查報告書
商品編碼
1935137
神經內分泌癌症治療市場按藥物類別、適應症類型、最終用戶、給藥途徑、通路和地區分類Neuroendocrine Carcinoma Treatment Market, By Drug Class, By Indication Type, By End User, By Route of Administration, By Distribution Channel, By Geography |
||||||
預計到 2026 年，神經內分泌癌症治療市場規模將達到 23.5 億美元，到 2033 年將達到 40.8 億美元，2026 年至 2033 年的複合年成長率為 8.2%。
| 報告內容 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 23.5億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 預測期（2026-2033年）複合年成長率： | 8.20% | 2033 年的預測值： | 40.8億美元 |
全球神經內分泌腫瘤治療市場是腫瘤治療領域的重要組成部分，旨在滿足神經內分泌腫瘤（NETs）和神經內分泌癌（NECs）患者複雜的臨床需求。這些罕見但日益受到重視的惡性腫瘤起源於分佈於包括胃腸道、胰臟、肺臟和其他解剖部位在內的各種器官系統的神經內分泌細胞。神經內分泌癌的特徵是異質性、分化程度不一以及臨床表現多樣，因此需要結合手術、全身性治療和分子標靶治療的綜合治療方法。
該市場涵蓋了廣泛的治療方法，包括生長抑制素類似物、標靶治療藥物、化療方案、胜肽受體放射性核素治療（PRRT）以及新興的免疫療法。隨著診斷技術的進步、對腫瘤生物學認知的加深以及醫療專業人員意識的提高，神經內分泌腫瘤的識別和治療取得了顯著進展。不斷上升的發病率和創新治療策略帶來的生存率提升，為市場提供了巨大的成長機會。這個專業治療市場持續吸引製藥公司的大量投資，推動著針對特定腫瘤特徵和患者情況的新型治療模式和個人化醫療方法的發展。
市場動態
全球神經內分泌腫瘤治療市場受多種強勁的市場促進因素推動，其中包括由於診斷技術的進步和醫療專業人員臨床意識的提高，全球神經內分泌腫瘤的發生率不斷上升。先進的影像技術、分子診斷和生物標記識別顯著提高了早期發現這些腫瘤的能力，從而擴大了需要治療性介入的患者群體。製藥公司不斷增加的研發投入正在加速創新治療方法的推出，例如標靶治療、免疫療法和精準醫療方法，與傳統化療方案相比，這些療法具有更高的療效和更低的副作用。
然而，該市場也面臨許多限制因素，主要源自於神經內分泌腫瘤的罕見性，這限制了符合臨床試驗條件的患者數量，也使得新型治療方法的監管核准面臨挑戰。高昂的治療費用，尤其是新型標靶治療和胜肽受體放射性核種療法（PRRT）的費用，可能給醫療系統和患者帶來沉重的經濟負擔，從而限制了市場准入。
此外，神經內分泌腫瘤的異質性使得治療標準化變得複雜，而基層醫療醫師對該疾病認知不足也可能導致診斷延遲和治療效果不佳。儘管面臨這些挑戰，不斷擴充的藥物研發管線、聯合治療的普及以及基於腫瘤遺傳學和患者個體因素的個人化治療策略的日益重視，都帶來了巨大的機會。開發中國家發病率的上升，加上醫療基礎設施的改善和醫療成本的增加，為致力於滿足神經內分泌腫瘤治療領域未滿足需求的製藥公司創造了巨大的市場拓展機會。
本次調查的主要特點
- 本報告對全球神經內分泌癌症治療市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模（十億美元）和復合年成長率（%）。
- 它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 該研究根據以下參數對全球神經內分泌癌症治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告的研究結果將使負責人和企業經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球神經內分泌癌症治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過各種策略矩陣更輕鬆地分析全球神經內分泌癌症治療市場，從而做出決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
第3章 市場動態、監管與趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 法規環境
- 產品上市及核准
- PEST分析
- 波特分析
- 併購趨勢
- 產業趨勢
4. 2021-2033年全球神經內分泌癌症治療市場（依藥物類別分類）
- 生長抑制素類似物
- 化療藥物
- 標靶治療藥物
- 免疫調節藥物
- 胜肽受體放射性核種治療（PRRT）
- 荷爾蒙
5. 2021-2033年全球神經內分泌腫瘤治療市場（依適應症類型分類）
- 胃腸胰神經內分泌腫瘤（GEP-NETs）
- 肺神經內分泌腫瘤
- 甲狀腺神經內分泌腫瘤
- 其他（例如，腎上腺神經內分泌腫瘤）
6. 2021-2033年全球神經內分泌腫瘤治療市場（依最終使用者分類）
- 醫院
- 癌症治療中心
- 門診手術中心
- 居家醫療
- 研究所
7. 2021-2033年全球神經內分泌腫瘤治療市場（依給藥途徑分類）
- 口服
- 腸外
8. 2021-2033年全球神經內分泌癌症治療市場（依通路分類）
- 醫院藥房
- 零售藥房
- 網路藥房
9. 2021-2033年全球神經內分泌腫瘤治療市場（依地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第10章 競爭格局
- Novartis AG
- Ipsen Pharma
- Pfizer Inc
- BristolMyers Squibb
- Eli Lilly and Company
- Merck &Co
- Amgen
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Hutchison China MediTech
- Exelixis Inc
- Chiasma Inc
- Advanced Accelerator Applications（Novartis Radioligand）
- Progenics Pharmaceuticals
- AbbVie Inc
第11章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第12章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
Neuroendocrine Carcinoma Treatment Market is estimated to be valued at USD 2.35 Bn in 2026 and is expected to reach USD 4.08 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.35 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 4.08 Bn |
The global neuroendocrine carcinoma treatment market represents a critical segment within the oncology therapeutics landscape, addressing the complex clinical needs of patients diagnosed with neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These rare but increasingly recognized malignancies arise from neuroendocrine cells distributed throughout various organ systems, including the gastrointestinal tract, pancreas, lungs, and other anatomical sites. Neuroendocrine carcinomas are characterized by their heterogeneous nature, varying degrees of differentiation, and diverse clinical presentations, necessitating sophisticated treatment approaches that combine surgical interventions, systemic therapies, and targeted molecular treatments.
The market encompasses a comprehensive range of therapeutic modalities including somatostatin analogs, targeted therapy agents, chemotherapy regimens, peptide receptor radionuclide therapy (PRRT), and emerging immunotherapeutic approaches. With advancing diagnostic capabilities, improved understanding of tumor biology, and growing awareness among healthcare professionals, the identification and treatment of neuroendocrine carcinomas have significantly evolved. The increasing incidence rates, coupled with enhanced survival outcomes through innovative treatment strategies, drives substantial market growth opportunities. This specialized therapeutic market continues to attract significant pharmaceutical investment, fostering the development of novel treatment paradigms and personalized medicine approaches tailored to specific tumor characteristics and patient profiles.
Market Dynamic
The global neuroendocrine carcinoma treatment market is propelled by several robust drivers, including the rising incidence of neuroendocrine tumors worldwide, attributed to improved diagnostic techniques and increased clinical awareness among healthcare professionals. Advanced imaging technologies, molecular diagnostics, and biomarker identification have significantly enhanced early detection capabilities, leading to expanded patient populations requiring therapeutic intervention. The growing investment in research and development by pharmaceutical companies has accelerated the introduction of innovative treatment modalities, including targeted therapies, immunotherapies, and precision medicine approaches that offer improved efficacy and reduced adverse effects compared to conventional chemotherapy regimens.
However, the market faces considerable restraints, primarily stemming from the rare nature of neuroendocrine carcinomas, which limits patient populations for clinical trials and creates challenges in achieving regulatory approvals for new treatments. High treatment costs, particularly for novel targeted therapies and peptide receptor radionuclide therapy, create significant financial burdens for healthcare systems and patients, potentially limiting market accessibility.
Additionally, the heterogeneous nature of neuroendocrine tumors complicates treatment standardization, while limited awareness among primary care physicians may result in delayed diagnoses and suboptimal treatment outcomes. Despite these challenges, substantial opportunities emerge from the expanding pipeline of investigational drugs, increasing adoption of combination therapy approaches, and growing focus on personalized treatment strategies based on tumor genetics and patient-specific factors. The rising prevalence in developing economies, coupled with improving healthcare infrastructure and increasing healthcare expenditure, presents significant market expansion opportunities for pharmaceutical companies seeking to address unmet medical needs in neuroendocrine carcinoma treatment.
Key Features of the Study
- This report provides in-depth analysis of the global neuroendocrine carcinoma treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuroendocrine carcinoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Ipsen Pharma, Pfizer Inc, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co, Amgen, Boehringer Ingelheim, Teva Pharmaceutical Industries, Hutchison China MediTech, Exelixis Inc, Chiasma Inc, Advanced Accelerator Applications (Novartis Radioligand), Progenics Pharmaceuticals, and AbbVie Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neuroendocrine carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine carcinoma treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Somatostatin Analogs
- Chemotherapeutic Agents
- Targeted Therapy Drugs
- Immunomodulatory Drugs
- Peptide Receptor Radionuclide Therapy (PRRT)
- Hormonal Agents
- Indication Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Pulmonary Neuroendocrine Tumors
- Thyroid Neuroendocrine Tumors
- Others (e.g. Adrenal Gland Neuroendocrine Tumors)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Cancer Treatment Centers
- Ambulatory Surgery Centers
- Home Care
- Research Institutes
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Ipsen Pharma
- Pfizer Inc
- Bristol Myers Squibb
- Eli Lilly and Company
- Merck & Co
- Amgen
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Hutchison China MediTech
- Exelixis Inc
- Chiasma Inc
- Advanced Accelerator Applications (Novartis Radioligand)
- Progenics Pharmaceuticals
- AbbVie Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neuroendocrine Carcinoma Treatment Market, By Drug Class
- Global Neuroendocrine Carcinoma Treatment Market, By Indication Type
- Global Neuroendocrine Carcinoma Treatment Market, By End User
- Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration
- Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel
- Global Neuroendocrine Carcinoma Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Neuroendocrine Carcinoma Treatment Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chemotherapeutic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunomodulatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Peptide Receptor Radionuclide Therapy (PRRT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hormonal Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Neuroendocrine Carcinoma Treatment Market, By Indication Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pulmonary Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Thyroid Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others (e.g. Adrenal Gland Neuroendocrine Tumors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Neuroendocrine Carcinoma Treatment Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Ambulatory Surgery Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Home Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Neuroendocrine Carcinoma Treatment Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BristolMyers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hutchison China MediTech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Exelixis Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiasma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced Accelerator Applications (Novartis Radioligand)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Progenics Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
神經內分泌腫瘤治療市場規模、佔有率和成長分析（按腫瘤類型、治療產品、部位、最終用途和地區分類）—產業預測（2026-2033 年）
神經內分泌腫瘤治療市場規模、佔有率、趨勢分析報告：按類型、產品、地點、最終用途、地區和細分市場進行預測，2025 年至 2030 年
神經內分泌腫瘤治療市場，按治療類型、藥物類別、腫瘤類型、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測全球神經內分泌腫瘤 (NET) 市場（2024 年版）：按治療、給藥途徑、適應症、最終用戶和區域、市場考慮因素和預測進行分析（2020-2030 年）